ResMed
About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Employees: 10,140
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]
51% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 72
23% more capital invested
Capital invested by funds: $17.2B [Q2] → $21.2B (+$3.99B) [Q3]
22% more repeat investments, than reductions
Existing positions increased: 312 | Existing positions reduced: 255
4% more funds holding
Funds holding: 757 [Q2] → 784 (+27) [Q3]
2.06% less ownership
Funds ownership: 61.34% [Q2] → 59.28% (-2.06%) [Q3]
58% less call options, than puts
Call options by funds: $258M | Put options by funds: $619M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JP Morgan David Low 0% 1-year accuracy 0 / 1 met price target | 23%upside $286 | Overweight Maintained | 31 Jan 2025 |
Keybanc Brett Fishbin 50% 1-year accuracy 9 / 18 met price target | 20%upside $280 | Overweight Maintained | 31 Jan 2025 |
Piper Sandler Adam Maeder 81% 1-year accuracy 13 / 16 met price target | 12%upside $260 | Neutral Maintained | 31 Jan 2025 |
Stifel Jonathan Block 21% 1-year accuracy 4 / 19 met price target | 7%upside $250 | Hold Initiated | 13 Dec 2024 |
Financial journalist opinion
Based on 17 articles about RMD published over the past 30 days









